ischemia/edema

BACKGROUND OF THE INVENTION Diabetes effects over 16 million Americans. The World Health Organization indicates that diabetes afflicts 120 million people worldwide, and estimates that this number will increase to 300 million by the year 2025. Diabetics are faced with numerous complications including

BACKGROUND OF THE INVENTION Diabetes affects over 16 million Americans. The World Health Organization indicates that diabetes afflicts 120 million people worldwide, and estimates that this number will increase to 300 million by the year 2025. Diabetics are faced with numerous complications including

BACKGROUND OF THE INVENTION Stroke remains the third most common cause of death in the industrial world, ranking behind ischemic heart disease and cancer. Strokes are responsible for about 300,000 deaths annually in the United States and about 11,000 deaths annually in Austria. Strokes are also a

FIELD OF THE INVENTION The inventive subject matter relates to a new use of L-butylphthalide in the prevention and treatment of cerebral ischemia-induced diseases, particularly to a use of L-butylphthalide in manufacturing the medicaments for the prevention and treatment of cerebral ischemia-induced

STATEMENT REGARDING FEDERAL SPONSORED RESEARCH AND DEVELOPMENT Not applicable. BACKGROUND OF THE INVENTION The subject of the present invention is, in the most general aspect, the prevention and/or treatment of a secondary edema. In particular, the present invention relates to a C1-Inhibitor for use

FIELD OF THE INVENTION The disclosure generally relates to the field of Neurology. More particularly, it relates to compositions and methods for treat neurological diseases associated with an increase in the permeability of the blood brain barrier (BBB), cerebral edema and/or cell death. BACKGROUND

FIELD OF THE INVENTION This invention relates to novel tricyclic vasopressin receptor antagonists. By interrupting the binding of the peptide hormone vasopressin to its receptors, the antagonists are useful for treating conditions involving increased vascular resistance and cardiac

This invention relates to novel tricyclic vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions involving increased vascular resistance and

FIELD OF THE INVENTION This invention relates to novel tricyclic vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions involving increased

FIELD OF THE INVENTION This invention is directed to certain novel [1,4]benzodiazepine compounds, their synthesis, and their use as vasopressin V2 receptor antagonists. More particularly, the compounds of the present invention interfere with the binding of the peptide hormone, vasopressin, to its

FIELD OF THE INVENTION This invention relates to novel nonpeptide substituted spirobenzazepines useful as, for example, vasopressin receptor antagonists. BACKGROUND OF THE INVENTION Vasopressin is a nonpeptide hormone that is secreted primarily from the posterior pituitary gland. The hormone effects

FIELD OF THE INVENTION This invention relates to novel nonpeptide substituted spiroheterobenzazepines useful as, for example, vasopressin receptor antagonists. BACKGROUND OF THE INVENTION Vasopressin is a nonapeptide hormone that is secreted primarily from the posterior pituitary gland. The hormone

FIELD OF THE INVENTION This invention relates to novel nonpeptide substituted spiroheterobenzazepines useful as, for example, vasopressin receptor antagonists. BACKGROUND OF THE INVENTION Vasopressin is a nonapeptide hormone that is secreted primarily from the posterior pituitary gland. The hormone

FIELD OF THE INVENTION This invention relates to novel nonpeptide substituted vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions

TECHNICAL FIELD Provided are novel prodrug salts of selective aquaporin inhibitors, e.g., of aquaporin-4 and/or aquaporin-2, of Formula I as described below, their use as pharmaceuticals and pharmaceutical compositions comprising them, and novel intermediates used in and novel processes for their